Embolic events in 93 elderly Chinese patients with atrial fibrillation

Chinese Medical Journal

Volumn 113, Issue 4, 2000, Pages 320-323

  Cao, Xuebin ^a   Wang, Shiwen ^b   Jiang, Long'an ^a   Liu, Lingling ^b   Huang, Heling ^a   Lu, Zengchun ^b  

^a The 252 Hospital of Chinese PLA   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Atrial fibrillation; Clinicopathology; Elderly patients; Embolism

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ARTICLE; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MALE; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; EMBOLISM; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED;

EID: 0039334817     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-1022.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987;147:1561-1564.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22:983-988.
4. Wolf PA, Dawber TA, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-978.
5. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
6. Zhang XY, Guo H, Wang XD. The discuss on incidence of cerebral embolism in heart disease patients with atrial fibrillation. Chin Med J Geriatric 1997;16:4.
7. Furberg CD, Psaty BM, Manodio TA, et al. For the CHS (cardiovascular health study) Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects. Am J Cardiol 1994;74:236-241.
8. Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992;326:1264-1271.
9. Aronow WS. Optimal management of older patients with atrial fibrillation. Drugs Aging 1994;4:184-193.
10. Wolf PA, Lewis A. Conner lecture: contributions of epidemiology to the prevention of stroke. Circulation 1993;88:2471-2478.
11. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986;17:622-626.
12. Daley R, Mattingly TW, Holt CL, et al. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951;42:566-581.
13. Stroke prevention in atrial fibrillation investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994;343:687-691.
14. Petersen P, Boysen G, Godtfredsen, et al. Placebo-controlled, randomised trial of warfwrin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-179.
15. The Boston Area Anticoagulation Trial Fibrillation Investigators. The effects of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323: 1505-1511.
16. Connoly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoaagulation study. J Am Coll Cardiol 1991;18:349-355.
17. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor strok. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-1262.